Key facts
- This page summarizes Robert Eugene Watson's Form 4 filing for CEL SCI CORP (CVM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2021, 17:34.
Robert Eugene Watson - 14 May 2021 Form 4 Insider Report for CEL SCI CORP (CVM)
- Reporting relationship
- Director
- Issuer ticker
- CVM
- Reported as of
- 14 May 2021
- Net transaction value
- +$1,280
- SEC form
- 4
- Accepted by SEC
- 17 May 2021, 17:34:55 UTC
- Next SEC filing
- 07 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- Robert Watson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Eugene Watson filed Form 4 for CEL SCI CORP (CVM) on 17 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$1,280.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVM
transaction
Derivative
Options
Award
- Transaction value
- $1,280
- Shares
- +128,000
- Change %
- +34%
- Price
- $0.0100*
- Shares after
- 506,000
- Date
- 14 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 128,000
- Exercise price
- $20.61
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022.